Opportunity Information: Apply for RFA AG 17 002
Apply for RFA AG 17 002
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Characterization of Circulating Pro- and Anti-Geronic Proteins and Peptides (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on Feb 24, 2016 and posted on Feb 24, 2016.
- Applicants must submit their applications by Feb 02, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This R01 funding opportunity (RFA-AG-17-002) supports research aimed at figuring out why and how aging-related traits can be transferred between young and old rodents when their circulatory systems are surgically joined, a setup known as heterochronic parabiosis. A central observation behind the program is that shared blood circulation can cause measurable, sometimes dramatic shifts in age-related biology. On the "anti-geronic" side, older animals exposed to young circulation have been reported to show improvements such as reversal of cardiac hypertrophy, partial recovery of cognitive performance, better vascularization, and enhanced skeletal muscle repair after injury. On the "pro-geronic" side, young animals exposed to old circulation can show earlier or accelerated declines, including losses in cognition and neurogenesis. The opportunity is anchored in the idea that these outcomes are not just vague systemic effects, but may be driven by specific, transferable molecules in blood.
The FOA focuses on "circulating geronic factors," defined here as candidate proteins and peptides present in the bloodstream that can pass between parabiotic partners once their vasculature connects (anastomoses). The scientific goal is not merely to catalog differences between young and old blood, but to rigorously test causality. Specifically, applicants are expected to determine whether particular candidate circulating factors are necessary for the observed transposition of aging phenotypes in heterochronic parabiosis. In other words, the program emphasizes experiments that move beyond correlation and directly interrogate whether a proposed factor must be present (or must be blocked, depleted, neutralized, or otherwise removed) for a given youthful or aged phenotype to appear in the partner animal.
A key boundary of the announcement is physiological relevance. The work is meant to concentrate on factors that are actually present and functional at normal circulating concentrations, and on phenotypes that have been demonstrated to transpose in the parabiosis paradigm (including established examples and other parabiosis-specific phenotypes reported in the literature). Taken together, the FOA is aimed at building a clearer mechanistic bridge between systemic circulating biology and age-related functional outcomes, using heterochronic parabiosis as the discovery and validation framework and using necessity-testing strategies to identify which circulating proteins or peptides truly drive pro-aging or anti-aging effects.
From an administrative standpoint, this is a discretionary NIH grant mechanism (R01) in the health area (CFDA 93.866) managed under HHS/NIH. The award ceiling listed is $350,000, with an anticipated total of about 6 awards. The opportunity was posted on February 24, 2016, with a closing date of February 2, 2017. Eligibility is broad and includes many types of domestic organizations, such as federal/state/local government entities, public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, tribal governments and organizations, public housing authorities/Indian housing authorities, for-profit organizations (other than small businesses), small businesses, and other categories as further clarified in the full eligibility text.
Frequently Asked Questions (FAQs)
What is the funding opportunity title/identifier?
This is an NIH R01 funding opportunity identified as RFA-AG-17-002.
What kind of grant mechanism is being offered?
The opportunity uses the NIH R01 research project grant mechanism and is described as a discretionary NIH grant.
Which agency is managing this opportunity?
The program is managed under HHS/NIH.
What is the CFDA number associated with this opportunity?
The CFDA number listed for this health-area opportunity is 93.866.
What is the overall scientific focus of this FOA?
The FOA supports research to understand why and how aging-related traits can be transferred between young and old rodents when their circulatory systems are surgically joined (heterochronic parabiosis). The underlying premise is that shared blood circulation can produce measurable changes in age-related biology, potentially driven by specific transferable molecules in blood.
What is heterochronic parabiosis in the context of this FOA?
Heterochronic parabiosis refers to a surgical setup where a young and an old rodent are joined so that, once their vasculature connects (anastomoses), they share blood circulation. This shared circulation has been reported to shift age-related phenotypes in both partners.
What are examples of the reported "anti-geronic" effects in older animals exposed to young circulation?
The FOA cites reported improvements in older animals exposed to young circulation, including reversal of cardiac hypertrophy, partial recovery of cognitive performance, better vascularization, and enhanced skeletal muscle repair after injury.
What are examples of the reported "pro-geronic" effects in young animals exposed to old circulation?
The FOA notes that young animals exposed to old circulation can show earlier or accelerated declines, including losses in cognition and neurogenesis.
What does the FOA mean by "circulating geronic factors"?
In this announcement, "circulating geronic factors" are defined as candidate proteins and peptides present in the bloodstream that can pass between parabiotic partners once their vasculature connects.
Is the goal to simply compare young versus old blood?
No. The FOA emphasizes that the goal is not merely to catalog differences between young and old blood, but to rigorously test causality related to phenotype transposition in heterochronic parabiosis.
What does "test causality" mean in this program?
Here, testing causality means determining whether a specific candidate circulating factor is necessary for the observed transfer (transposition) of aging-related phenotypes between parabiotic partners.
What does it mean for a factor to be "necessary" under this FOA?
The FOA is centered on experiments that directly interrogate whether a proposed factor must be present for a youthful or aged phenotype to appear in the partner animal. Examples mentioned include approaches where a factor is blocked, depleted, neutralized, or otherwise removed to see whether the phenotype still occurs.
What kinds of molecules are in-scope for the circulating factors described here?
The announcement specifically targets candidate proteins and peptides in the bloodstream that can be transferred between parabiotic partners.
Does the FOA require physiological relevance of the candidate factors?
Yes. A key boundary is physiological relevance: the work should concentrate on factors that are actually present and functional at normal circulating concentrations.
What kinds of phenotypes should the proposed studies focus on?
The FOA indicates a focus on phenotypes that have been demonstrated to transpose in the parabiosis paradigm, including established examples and other parabiosis-specific phenotypes reported in the literature.
What is the main purpose of using heterochronic parabiosis in this program?
Heterochronic parabiosis is positioned as the discovery and validation framework to help build a clearer mechanistic bridge between systemic circulating biology and age-related functional outcomes, with an emphasis on necessity-testing to identify which circulating proteins or peptides drive pro-aging or anti-aging effects.
What is the award ceiling for this opportunity?
The listed award ceiling is $350,000.
How many awards are anticipated?
The opportunity anticipates a total of about 6 awards.
When was this opportunity posted?
The opportunity was posted on February 24, 2016.
What was the closing date for applications?
The closing date listed is February 2, 2017.
Who is eligible to apply?
Eligibility is described as broad and includes many types of domestic organizations, including: federal/state/local government entities; public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); tribal governments and organizations; public housing authorities/Indian housing authorities; for-profit organizations (other than small businesses); small businesses; and other categories as further clarified in the full eligibility text.
Are both nonprofit and for-profit organizations eligible?
Yes. The eligibility description includes nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses.
Are government and tribal entities eligible?
Yes. The eligibility description includes federal/state/local government entities, tribal governments, and tribal organizations.
Is this opportunity limited to U.S. (domestic) organizations?
The eligibility description explicitly references many types of domestic organizations.
What is the central hypothesis driving the FOA?
The FOA is anchored in the idea that the observed shifts in age-related biology in parabiosis are not just vague systemic effects, but may be driven by specific, transferable molecules in blood, and that rigorous experiments can identify which proteins or peptides truly drive the effects.
What is the key experimental emphasis highlighted by the FOA?
The key emphasis is on necessity-testing strategies (for example, blocking, depleting, neutralizing, or otherwise removing a candidate factor) to determine whether that factor is required for the transposition of aging phenotypes in heterochronic parabiosis.
Browse more opportunities from the same category: Health
Next opportunity: Maximizing Access to Research Careers Undergraduate - Student Training in Academic Research (MARC U-STAR) (T34)
Previous opportunity: National Organizations’ Support for State Oral Health Programs
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 17 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 17 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Maximizing Access to Research Careers Undergraduate - Student Training in Academic Research (MARC U-STAR) (T34) Apply for PAR 16 113 Funding Number: PAR 16 113 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Improving Fetal Alcohol Spectrum Disorders Prevention and Practice through National Partnerships Apply for CDC RFA DD14 140303CONT16 Funding Number: CDC RFA DD14 140303CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Center without Walls for the Identification and Validation of Molecular Mechanisms Contributing to Tau Pathogenesis and Associated Neurodegeneration in Frontotemporal Degeneration (FTD) (U54) Apply for RFA NS 16 023 Funding Number: RFA NS 16 023 Agency: HHS-NIH11 Category: Health Funding Amount: $1,500,000 |
| Empowering Older Adults and Adults with Disabilities in Tribal Communities through Chronic Disease Self-Management Education Programs Financed Solely by 2016 Prevention and Public Health Funds (PPHF-2016) Apply for HHS 2016 ACL AOA CS 0129 Funding Number: HHS 2016 ACL AOA CS 0129 Agency: HHS-ACL Category: Health Funding Amount: $150,000 |
| Cooperative Study Group for Autoimmune Disease Prevention (U01) Apply for RFA AI 16 003 Funding Number: RFA AI 16 003 Agency: HHS-NIH11 Category: Health Funding Amount: $1,600,000 |
| Stimulating Peripheral Activity to Relieve Conditions (SPARC): Pre-clinical Development of Existing Market-approved Devices to Support New Market Indications (U18) Apply for RFA RM 16 009 Funding Number: RFA RM 16 009 Agency: HHS-NIH11 Category: Health Funding Amount: $400,000 |
| Public Health Surveillance for the Prevention of Complications of Bleeding Disorders Apply for CDC RFA DD15 150702CONT16 Funding Number: CDC RFA DD15 150702CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement with the Chinese Center for Disease Control and Prevention Apply for CDC RFA GH12 124705CONT16 Funding Number: CDC RFA GH12 124705CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01) Apply for PAR 16 115 Funding Number: PAR 16 115 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Addiction Technology Transfer Center: Networking Coordinating Office for Internationally-based Addiction Technology Transfer Centers (Short Title: Global-ATTC) Apply for TI 16 015 Funding Number: TI 16 015 Agency: HHS-SAMHS Category: Health Funding Amount: $100,000 |
| Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Consortium: Coordinating Center (U24) Apply for RFA NS 16 019 Funding Number: RFA NS 16 019 Agency: HHS-NIH11 Category: Health Funding Amount: $750,000 |
| Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy Apply for CDC RFA DP14 140703CONT16 Funding Number: CDC RFA DP14 140703CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Defeat Malaria Apply for RFA 482 16 000001 Funding Number: RFA 482 16 000001 Agency: USAID-BMA Category: Health Funding Amount: $32,000,000 |
| Improving Response to and Programming in Humanitarian Emergencies Apply for CDC RFA GH15 162302CONT16 Funding Number: CDC RFA GH15 162302CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pragmatic Strategies for Assessing Psychotherapy Quality in Practice (R01) Apply for RFA MH 17 500 Funding Number: RFA MH 17 500 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Development Projects (UH2/UH3) Apply for RFA NS 16 020 Funding Number: RFA NS 16 020 Agency: HHS-NIH11 Category: Health Funding Amount: $750,000 |
| Partner Support for Heart Disease and Stroke Prevention Apply for CDC RFA DP15 150402CONT16 Funding Number: CDC RFA DP15 150402CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| National Public Health Practice and Resource Centers for Children with Attention Deficit/Hyperactivity Disorder or Tourette Syndrome Apply for CDC RFA DD15 150502CONT16 Funding Number: CDC RFA DD15 150502CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Strategic Approaches to Improving Access to Quality Health Care for Children and Youth with Epilepsy Apply for HRSA 16 055 Funding Number: HRSA 16 055 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Developing professional training programs to increase capacity for effective global health response to humanitarian emergencies Apply for CDC RFA GH15 162402CONT16 Funding Number: CDC RFA GH15 162402CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 17 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.